Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease

समान संसाधन

• Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
  द्वारा: Walters, M, और अन्य
  प्रकाशित: (2010)
• Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
  द्वारा: Keshav, S, और अन्य
  प्रकाशित: (2007)
• Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
  द्वारा: Bekker, P, और अन्य
  प्रकाशित: (2007)
• CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease.
  द्वारा: Wendt, E, और अन्य
  प्रकाशित: (2015)
• CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease
  द्वारा: Wendt E, और अन्य
  प्रकाशित: (2015-04-01)